Founded in 2016, CELLINK is a global bio-convergence company that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, analysis, and liquid handling and bioprocessing, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform highthroughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries.
CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 150 publications.
CellAct Pharma develops innovative chemotherapeutics for the treatment of cancer.
CellAct's leading clinical candidate CAP7.1 has been developed at the Charité university clinic in Berlin and is a novel modification of the established chemotherapeutic agent Etoposide. CAP7.1 has the essential advantage of being able to concentrate in solid tumors. This increases the efficacy and reduces side effects. CAP7.1 has shown impressive results in clinical studies, extending survival time of patients treated for solid tumors such as lung and biliary tract cancer in the final stages.
The program is currently in preparation for an international Phase III study to achieve marketing authorization in Europe and the US.
Life Sciences /
We participate in a venture capital fund (CBF-1), which invests in young companies in the healthcare sector. We manage this fund with our strong partners through Peppermint VenturePartners GmbH. The CBF-1 investment portfolio currently includes eight companies from the fields of medical technology, diagnostics and digital health as well as platform technologies in the healthcare sector, who have convinced us with their innovative ideas.
authentic is a blockchain based authenticity certification.
Blockchain technology ensures the authenticity and originality of products, medicines and documents through the combination of patented printing and scanning technology.
ETHCL Food Labs GmbH
Healthy nutrition is very important to us. Especially in hectic times, it matters to have a healthy snack. Peppermint therefore has a stake in ETHCL Food Labs GmbH, which combines the OH MY DOUGH and TZAMPAS brands. The Berlin start-up offers the ready-to-eat biscuit dough OH MY DOUGH for snacking in organic quality and TZAMPAS energy bars as well as other products based on the roasted barley flour of the same name. The naturalness of the ingredients has top priority.